What term describes the observational and epidemiologic studies that identify rare toxicity after a drug has been used widely?

• A. Post-marketing surveillance
• B. Preclinical testing
• C. Phase 1 trial
• D. Pharmacovigilance

Answer: (A)

After a drug is released and used by large populations, rare adverse effects may only become evident in real-world settings. This is post-marketing surveillance—the observational and epidemiologic work that detects uncommon toxicities that didn’t appear in smaller pre-approval trials. By collecting reports, conducting cohort or case-control studies, and analyzing safety signals in the broader patient population, researchers can identify risks, quantify how often they occur, and inform labeling changes or safety measures.

Preclinical testing refers to animal studies before humans. Phase 1 trials are initial safety tests in a small number of humans. Pharmacovigilance is the broader discipline of monitoring drug safety, of which post-marketing surveillance is a key component. The description given matches post-marketing surveillance because it centers on detecting rare toxicity after widespread use.